Michael Peterson, PA
Physician Assistant · Mentor, OHNPI 1861542086
Payments from drug & device makers
Across 319 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Pfizer$726
- AstraZeneca$590
- Lilly USA, LLC$582
- GSK$405
- AbbVie$376
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,010100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $1,059 |
| Pfizer | 44 | $726 |
| AstraZeneca | 24 | $590 |
| Lilly USA, LLC | 38 | $582 |
| GSK | 22 | $405 |
| AbbVie | 16 | $376 |
| Amgen | 23 | $371 |
| Phathom Pharmaceuticals, Inc. | 15 | $224 |
| Exact Sciences | 11 | $223 |
| Merck | 11 | $176 |
| Boston Scientific | 2 | $170 |
| Astellas Pharma US Inc | 6 | $132 |
| Boehringer Ingelheim | 7 | $104 |
| Xeris Pharmaceuticals, Inc. | 5 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $93 |
| E.r. Squibb & Sons, L.L.C. | 5 | $92 |
| Sanofi-aventis U.S. LLC | 4 | $86 |
| Abbott | 4 | $76 |
| Bayer | 4 | $71 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $61 |
| Johnson & Johnson | 4 | $54 |
| Biohaven Pharmaceuticals, Inc. | 3 | $46 |
| Corcept Therapeutics | 2 | $39 |
| Antares Pharma, Inc. | 2 | $34 |
| TMS Neurohealth Centers Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $13 |
| Radius Health, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,010 in reported general payments places this provider in the 95th percentile of 4,098 physician assistant providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 128 | $185,101 |
| MounjaroTirzepatide | 55 | $59,557 |
| FarxigaDapagliflozin Propanediol | 48 | $51,103 |
| EliquisApixaban | 52 | $44,145 |
| JardianceEmpagliflozin | 46 | $37,799 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $28,745 |
| TrulicityDulaglutide | 25 | $28,021 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $24,769 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 60 | $21,317 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $16,206 |
| OxycontinOxycodone Hcl | 12 | $11,922 |
| Spiriva RespimatTiotropium Bromide | 20 | $11,072 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $9,510 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $4,596 |
| Atorvastatin Calcium | 320 | $2,976 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,059 | $185,101128 claims |
| Lilly USA, LLCMounjaro, Trulicity | $582 | $87,57880 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere | $590 | $71,90584 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $104 | $48,87166 claims |
| PfizerEliquis, Premarin | $726 | $46,56664 claims |
| GSKTrelegy Ellipta | $405 | $24,76935 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $86 | $21,31760 claims |
| AbbVieSynthroid | $376 | $2,05426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,098 physician assistant providers in Ohio.
Other physician assistant in Mentor
- Rachel McKernanMentor$13K
- Steven WurzelbacherCincinnati$309K
- Emily AnkromDayton$192K
- Amanda MaggartWorthington$164K
- Megan SevillaMayfield Heights$132K
- Erin StrculaBelpre$106K
- Natalie WalkupSylvania$105K
- Sarah LaubNew Albany$100K
- Jessica RhominskiCanal Winchester$78K
- Alan OdonnellCincinnati$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.